SCHEMBL3748980

SCHEMBL3748980

CCCCCCC(=O)CC(=O)N(C)c1ccccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
HAO1 Q9UJM8 1/20 0.42
EPHX2 P34913 1/20 0.42
PLK1 P53350 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
PTPN1 P18031 1/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
ASAH1 Q13510 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
PLK3 Q9H4B4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3739641 1.00 POLB (0.42) POLBTSHRHAO1EPHX2PLK1
SCHEMBL3731040 0.89 TSHR (0.45) POLBTSHREPHX2PLK1CES2
SCHEMBL3735946 0.87 KMT2A (0.46) POLBTSHRPTPN1KMT2AKDM4E
SCHEMBL3744823 0.84 ALDH1A1 (0.51) POLBTSHRHAO1EPHX2CES2
SCHEMBL3731228 0.84 ALDH1A1 (0.51) POLBTSHRHAO1EPHX2CES2
SCHEMBL13041480 0.83 POLB (0.47) POLBTSHRPTPN1KDM4EALDH1A1
SCHEMBL10602287 0.82 SOAT2 (0.51) POLBTSHREPHX2CES1PTPN1
SCHEMBL3735202 0.82 EPHX2 (0.50) HAO1EPHX2CES2CES1ASAH1
SCHEMBL3742708 0.82 EPHX2 (0.50) HAO1EPHX2CES2CES1ASAH1
SCHEMBL3744798 0.81 HDAC6 (0.44) EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280034-A1 Modulation of pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-7338969-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-03-04 US disclosed
US-20070208012-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-09-06 US disclosed
US-20070203128-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-30 US disclosed
US-20070197492-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-23 US disclosed
US-20070196340-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-23 US disclosed
US-20070184014-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-08-09 US disclosed
US-20070093534-A1 Modulation of Pathogenicity QUONOVA, LLC 2007-04-26 US disclosed
US-20040235914-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197492-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS POLB 3582/4885TSHR 2025/4885HAO1 3181/4885
US-20070203128-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS POLB 3582/4885TSHR 2025/4885HAO1 3181/4885
US-20070093534-A1 Modulation of Pathogenicity NR1H4, NR1I3, NR1H2 POLB 3696/4885TSHR 803/4885HAO1 588/4885
US-20040235914-A1 Modulation of pathogenicity Q6ZSR9, CCL11, CFH POLB 2177/4885TSHR 185/4885HAO1 711/4885
US-20070208012-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS POLB 3582/4885TSHR 2025/4885HAO1 3181/4885
US-20100280034-A1 Modulation of pathogenicity NR1H4, NR1I3, NR1H2 POLB 3696/4885TSHR 803/4885HAO1 588/4885
US-20070184014-A1 Modulation of Pathogenicity ANTXR2, Q6ZSR9, PGLS POLB 3582/4885TSHR 2025/4885HAO1 3181/4885
US-20070196340-A1 Modulation of Pathogenicity NR1H4, NR1I3, NR1H2 POLB 3696/4885TSHR 803/4885HAO1 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.